A socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Roscongress Foundation is a socially oriented non-financial development institution and a major organizer of international conventions; exhibitions; and business, public, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 160 economic partners; industrialists’ and entrepreneurs’ unions; and financial, trade, and business associations from 75 countries worldwide.

The Roscongress Foundation has Telegram channels in Russian (t.me/Roscongress), English (t.me/RoscongressDirect), and Spanish (t.me/RoscongressEsp). Official website and Information and Analytical System of the Roscongress Foundation: roscongress.org.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Yuriy Zhulev

Yuriy Zhulev

President, Russian Hemophilia Society
Quotes
05.06.2021
SPIEF 2021
Healthcare as Investment: Public and Private Partnership in the Pharmaceutical Sector
During the pandemic, we conducted a survey on the delivery of subsidized medicines to patients. You know, even for a particular disease, when we analyzed the respondents’ answers, we could not understand what was happening. There were totally contradicting answers in terms of accessibility and delivery, not only between the regions, but even within the regions
05.06.2021
SPIEF 2021
Healthcare as Investment: Public and Private Partnership in the Pharmaceutical Sector
We are deeply convinced that this should be strictly centralized. You know, they will tell me right away that there is regional specificity. I agree with that, but we would like to see regional specificity in terms of improving the availability of quality medicinal supply, and not the other way around, as it is happening now. There are regions <...> that are quite advanced in terms of the models for drug provision, and then there are regions where the law can only be implemented with a court ruling
08.06.2019
SPIEF 2019
Priority Strategies in the Supply of Drugs
We are wasting time in every area, in registering medicines, and in securing access to new technologies. <...> We are wasting time in procurement, we are wasting time in joining the list of subsidized drugs, and we are wasting time at the beginning of treatment
08.06.2019
SPIEF 2019
Priority Strategies in the Supply of Drugs
Our drug supply programme is not currently fair
08.06.2019
SPIEF 2019
Priority Strategies in the Supply of Drugs
Quick access to drug therapy is an extremely important factor when it comes to implementing these projects
13.02.2019
Healthy Life Forum: Towards 80+ 2019
A System of Universal Medicine Provision: Key to Achieving the National Goal
We will not achieve the goals established by the President if we are working from the current position on medicine provision benefits: ‘Become disabled, and then we’ll give you medicine.” There can’t be any talk of 80+ or quality of life in that case. There must be a unified principle differentiating subsidies depending on the illness. The government must get involved in universal medicine provisioning at the earliest possible stage